Recent Finacing
Recent Raise
Nammi Therapeutics develops tumor‑microenvironment‑targeted immunotherapies and nanoparticle delivery systems, including a Masked Immunocytokine (QXL138AM) and Nammisome/Namm‑1 co‑delivering chemo‑immunotherapy.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at Nammi Therapeutics.
